Hematopoietic stem and progenitor cell harvesting: Technical advances and clinical utility

Journal of Blood Medicine

Volumn 6, Issue , 2015, Pages 55-67

  Hequet, Olivier ^a,b  

^a CENTRE HOSPITALIER   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Apheresis; Bone marrow; Cord blood; Harvesting; Hematopoietic stem cell; Mobilization; Peripheral blood

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; LENALIDOMIDE; THALIDOMIDE;

APHERESIS; ARTICLE; BONE MARROW; CELL COUNT; CELL DENSITY; CELL ISOLATION; CLINICAL PROTOCOL; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ORGAN DONOR; PATIENT SAFETY; PERIPHERAL CIRCULATION; STEM CELL MOBILIZATION; UMBILICAL CORD BLOOD;

EID: 84939121650     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S52783     Document Type: Article

References (109)

1. Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow in man. J Clin Invest. 1959;38:1709–1716.
2. Armitage JO. Bone marrow transplantation. N Eng J Med. 1994; 330(12):827–838.
3. McCredie KB, Hersh EM, Freirich EJ. Cells capable of colony formation in the peripheral blood of man. Science. 1971;171(3968):293–294.
4. Lu L, Xiao M, Shen RN, Gribgsby S, Broxmeyer HE. Enrichment, characterization, and responsiveness of single primitive cord blood hematopoietic progenitors with high proliferative and replating potential. Blood. 1993;81(1):41–48.
5. Gluckman E, Broxmeyer H, Auerbach A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989; 321(17):1174–1178.
6. Rocha V, Labopin M, Gluckman E, et al; Acute Leukemia Working Party of the European Blood and Marrow Transplant Registry. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol. 2002;20(21):4324–4330.
7. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant. 1997;20(12):1033–1037.
8. Kao RH, Li CC, Shaw CK, et al. Correlation between characteristics of unrelated bone marrow donor and cell density of total nucleated cell in bone marrow harvest. Int J Hematol. 2009;89(2):227–230.
9. Bacigalupo A, Tong J, Podesta M, et al. Bone marrow harvest for marrow transplantation: effect of multiple small (2 mL) or large (20 mL) aspirates. Bone Marrow Transplant. 1992;9(6):467–470.
10. Wang TF, Chu SC, Chen SH, et al. The effect of different harvest strategies on the nucleated cell yields of bone marrow collection. Biol Blood Marrow Transplant. 2011;17(3):351–355.
11. Tanikawa S, Sakamaki H, Mori S, et al. Relationship between the presence of side-holes in bone marrow aspiration needle and the number of harvested bone marrow mononuclear cells. Rinsho Ketsueki. 1997;38(12):1249–1253.
12. Bouwmeester W, Fechter MM, Heymans MW, Twisk JW, Ebeling LJ, Brand A. Prediction of nucleated cells in bone marrow stem cell products by donor characteristics: a retrospective single centre analysis. Vox Sang. 2010;98(3):276–283.
13. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86(10):3828–3832.
14. Gluckman E. European organization for cord blood banking. Blood Cells. 1994;24(2–3):601–608.
15. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347.
16. Armson BA. Maternal/fetal medicine committee, society of obstetricians and gynaecologists of Canada. Umbilical cord blood banking: implications for perinatal care providers. J Obstet Gynaecol Can. 2005;27(3):263–290.
17. Lauber S, Latta M, Klüter H, Müller-Steinhardt M. The Mannheim Cord Blood Bank: experiences and perspectives for the future. Transfus Med Hemother. 2010;37(2):90–97.
18. Solves P, Moraga R, Saucedo E, et al. Comparison between two strategies for umbilical cord blood collection. Bone Marrow Transplant. 2003;31(4):269–273.
19. Aroviita P, Teramo K, Westman P, Hiilesmaa V, Kekomäki R. Associations among nucleated cell, CD34+ cell and colony-forming cell contents in cord blood units through a standardized banking process. Vox Sang. 2003;84(3):219–227.
20. Page KM, Mendizabal A, Betz-Stablein B, et al. Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality. Transfusion. 2014;54(2):340–352.
21. Keersmaekers CL, Mason BA, Keersmaekers J, Ponzini M, Mlyanarek RA. Factors affecting umbilical cord blood stem cell suitability for transplantation in an in utero collection program. Transfusion. 2014;54(3):545–549.
22. Fasouliotis SJ, Schenker MD. Human umbilical cord blood banking and transplantation: a state of the art. Eur J Obstet Gynecol Reprod Biol. 2000;90(1):13–25.
23. Bertolini F, Lazzari L, Lauri E, et al. A comparative study of different procedures for the collection and banking of umbilical cord blood. J Hematother. 1995;4(1):29–36.
24. Elchalal U, Fasouliotis SJ, Shtockheim D, et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstet Gynecol. 2000;182(1):227–232.
25. Belvedere O, Feruglio C, Malangone W, et al. Increased blood volume and CD34+CD38- cell recovery using a novel umbilical cord blood collection system. Stem Cells. 2000;18(4):245–251.
26. Bornstein R, Flores AI, Montalbán MA, Del Rey D, de la Serna J, Gilsanz F. A modified cord blood collection method achieves sufficient cell levels for transplantation in most adult patients. Stem Cells. 2005;23(3):324–334.
27. Takebe N, Gage F, Cheng X, Lauw MIS. Preliminary findings on the use of a pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions. Transfusion. 2009;49(9):1911–1916.
28. Tan KK, Tang KZ, Huang S, et al. Ex utero harvest of hematopoietic stem cells from placenta/umbilical cord with an automated collection system. IEEE Trans Biomed Eng. 2009;56(9):2331–2334.
29. Surbek DV, Schönfeld B, Tichelli A, Gratwohl A, Holzgreve W. Optimizing cord blood mononuclear cell yield: a randomized comparison of collection before vs after placenta delivery. Bone Marrow Transplant. 1998;22(3):311–312.
30. Lasky LC, Lane TA, Miller JP, et al. In utero or ex utero cord blood collection: which is better? Transfusion. 2002;42(10):1261–1267.
31. Wong A, Yuen PM, Li K, Tsoi WC. Cord blood collection before and after placental delivery: levels of nucleated cells, haematopoietic progenitor cells, leukocyte subpopulations and macroscopic clots. Bone Marrow Transplant. 2001;27(2):133–138.
32. Omori A, Manabe M, Kudo K, Tanaka K, Takahashi K, Kashiwakura I. Influence of obstetric factors on the yield of mononuclear cells, CD34+ cell count and volume of placental/umbilical cord blood. J Obstet Gynaecol Res. 2010;36(1):52–57.
33. Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion. 2005;45(6):856–866.
34. Jan RH, Wen SH, Shyr MH, Chiang BL. Impact of maternal and neonatal factors on CD34+ cell count, total nucleated cells, and volume of cord blood. Pediatr Transplant. 2008;12(8):868–873.
35. Cobellis L, Castaldi MA, Trabucco E, et al. Cord blood unit bankability can be predicted by prenatal sonographic parameters. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):391–395.
36. Liu J, He J, Chen S, et al. Cord blood banking and transplantation in China: a ten years experience of a single public bank. Transfus Med Hemother. 2012;39(1):23–27.
37. Jawdat D, Arab S, Thahery H, Almashaqbeh W, Alaskar A, Hajeer AH. Improving cord blood unit quantity and quality at King Abdullah International Medical Research Center Cord Blood Bank. Transfusion. Epub June 9, 2014.
38. Clark P, Trickett A, Stark D, Vowels M. Factors affecting microbial contamination rate of cord blood collected for transplantation. Transfusion. 2012;52(8):1770–1777.
39. Warkentin PI. Foundation for the accreditation of cellular therapy. Voluntary accreditation of cellular therapies: foundation for the accreditation of cellular therapy (FACT). Cytotherapy. 2003;5(4): 299–305.
40. Anguita-Compagnon AT, Dibarrart MT, Palma J, et al. Mobilization and collection of peripheral blood stem cells: guidelines for blood volume to process, based on CD34-positive blood cell count in adults and children. Transplant Proc. 2010;42(1):339–344.
41. Chen J, Burns KM, Babic A, et al. Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor. Transfusion. 2014;54(1):203–210.
42. Bertani G, Santoleri L, Martino M, et al. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization results in an Italian multicenter study. Transfusion. 2014;54(8): 2028–2033.
43. Al-Ali HK, Bourgeois M, Krahl R, et al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46(10):1296–1302.
44. Billen A, Madrigal JA, Szydlo RM, Shaw BE. Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation. Transfusion. Epub May 27, 2014.
45. Hauge AW, Haastrup EK, Sengeløv H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion. 2014;54(4):1055–1058.
46. de Latour RP, Chaoui D, Bourhis JH, et al. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma. Leuk Lymphoma. 2007;48(5):897–904.
47. Endo T, Sato N, Mogi Y, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33(7):703–707.
48. Cesaro S, Tintori V, Nesi F, et al. A prospective study on the efficacy of mobilization of autologous peripheral stem cells in pediatric oncohematology patients. Transfusion. 2013;53(7):1501–1509.
49. Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematological malignancies. Biol Blood Marrow Transplant. 2012;18(8):1191–1203.
50. Jung SH, Park H, Ahn JS, et al. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. Int J Hematol. 2013;97(1):92–97.
51. Bhutani D, Zonder J, Valent J, et al. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer. 2013;21(9):2437–2442.
52. Martínez E, Sureda A, Dalmases CD, et al. Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma. Bone Marrow Transplant. 1996;18(1):1–7.
53. Publicover A, Richardson DS, Davies A, et al. Use of biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013;162(1):107–111.
54. Weisdorf D, Miller J, Verfaillie C, et al. Cytokine-primed bone marrow stem cells vs peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs G-CSF. Biol Blood Marrow Transplant. 1997;3(4):217–223.
55. Herbert KE, Gambell P, Link EK, et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013;48(3):351–356.
56. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13(10):2547–2555.
57. Weaver CH, Schwartzberg LS, Birch R, et al. Collection of peripheral blood cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion. 1997;37(9):896–903.
58. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor in 200 patients with lymphoid malignancies. Br J Haematol. 1998;103(1):235–242.
59. Mendrone A, Arrais CA, Saboya R, Chamone DAF, Dulley FL. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci. 2008;39(3):187–192.
60. Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion. 2004;44(5):777–784.
61. Lacativa CP, Lacativa PG, Garnica M, et al. Risk factors for unsuccessful peripheral blood stem cell harvesting using granulocyte-colony stimulating factor mobilization in patients with multiple myeloma. Transfus Apher Sci. 2012;47(3):331–335.
62. Waterman J, Rybicki L, Bolwell B, et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(4):488–493.
63. Moreau P, Hulin C, Marit G, et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia. 2010;24(6):1233–1235.
64. Cavallo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma lenalidomide induction therapy. Leukemia. 2011;25(10):1627–1631.
65. Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of “just in time” salvage plerixaflor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011;51(10):2175–2182.
66. Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 2012;18(2):241–249.
67. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–351.
68. Perseghin P, Terruzzi E, Dassi M, et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci. 2009;41(1): 33–37.
69. Wuchter P, Ran D, Bruckner T. Poor mobilization of hematopoieic stem cells–definition, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16(4):490–499.
70. Watts MJ, Sullivan AM, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol. 1998;16(4):1554–1560.
71. Reiser M, Josting A, Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant. 1999;23(12):1223–1228.
72. Lie AK, Hui CH, Rawling T, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant. 1998;22(9): 853–857.
73. Pérez-Dueñas B, Alcorta I, Estella J, Rives S, Toll T, Tuset E. Safety and efficacy of high-dose G-CSF (24 microg/kg) alone for PBSC mobilization in children. Bone Marrow Transplant. 2002;30(12): 987–988.
74. Facon T, Harousseau JL, Maloisel F, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized controlled trial. Blood. 1999;94(4):1218–1225.
75. Lapierre V, Rossi JF, Heshmati F, et al. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience. Bone Marrow Transplant. 2011;46(7):936–942.
76. Shaughnessy P, Uberti J, Devine S, et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013;48(6):777–781.
77. Herbert KE, Demosthenous L, Wiesner G, et al. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplant. 2014;49(8):1056–1062.
78. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011;46(1):64–69.
79. Schots R, Van Riet I, Damiaens S, et al. The absolute number of circulating CD34+ cells predicts the number of haematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant. 1996;17(4):509–515.
80. Lane TA, Bashey A, Carrier E, et al. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy. 2004;6(4):318–327.
81. Menichella G, Lai M, Serafini R, et al. Large volume leukapheresis for collecting hemopoietic progenitors: role of CD 34+ precount in predicting successful collection. Int J Artif Organs. 1999;22(5):334–341.
82. Wu FY, Heng KK, Salleh RB, et al. Comparing peripheral blood stem cell collection using the COBE Spectra, Haemonetics MCS+, and Baxter Amicus. Transfus Apher Sci. 2012;47(3):345–350.
83. Ikeda K, Ohto H, Nemoto K, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion. 2003;43(6):814–819.
84. Schreiner T, Wiesneth M, Krug E, et al. Collection of allogeneic peripheral blood progenitor cells by two protocols on an apheresis system. Transfusion. 1998;38(11–12):1051–1055.
85. Altuntas F, Kocyigit I, Ozturk A, et al. Comparison of the Fenwal Amicus and Fresenius Com.Tec cell separators for autogous peripheral blood progenitor cell collection. Transfus Apher Sci. 2007;36(2):159–167.
86. Reinhardt P, Brauninger S, Bialleck H, et al. Automatic inter-face controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device. Transfusion. 2011;51(6):1321–1330.
87. Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H. Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems. Transfusion. 2012; 52(5):1137–1145.
88. Flommersfeld S, Bakchoul T, Bein G, Wachtel A, Loechelt C, Sachs UJ. A single center comparison between three different apheresis systems for autologous and allogeneic stem cell collections. Transfus Apher Sci. 2013;49(3):428–433.
89. Ikeda K, Ohto H, Kanno T, et al. Peripheral blood cell progenitor cell collection by two programs for autologous and allogeneic transplantation. Transfusion. 2014;54(5):1235–1242.
90. Cherqaoui B, Rouel N, Auvrignon A, et al. Peripheral blood stem collection in low-weight children: retrospective comparison of two apheresis devices. Transfusion. 2014;54(5):1371–1378.
91. Andreola G, Vanazzi A, Radice D, et al. Who should be really considered as a poor mobilizer in the plerixafor era? Transfus Apher Sci. 2012;47(1):27–32.
92. Bojanic I, Dubravcic K, Batinic D, et al. Large volume leukapheresis: efficacy and safety of processing patient’s total blood volume six times. Transfus Apher Sci. 2011;44(2):139–147.
93. Ng HN, Sim KM, Boey SK. Bone marrow harvesting using EMLA (eutectic mixture of local anaesthesics) cream, local anaesthesia and patient-controlled analgesia with alfentanil. Bone Marrow Transplant. 1999;23(9):941–945.
94. van Walraven SM, Straathof LM, Switzer GE, et al. Immediate and long-term somatic effects, and health-related quality of life of BM donation during early childhood. A single-center report in 210 pediatric donors. Bone Marrow Transplant. 2013;48(1):40–45.
95. Lazzari L, Corsini C, Curioni C, et al. The Milan Cord Blood Bank and the Italian Cord Blood Network. J Hematother. 1996;5(2):117–122.
96. Chen SH, Yang SH, Chu SC, et al. The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization. Int J Hematol. 2011;93(5):652–659.
97. Akyol G, Pala C, Yildirim A, et al. A rare but severe complication of filgrastim in a healthy donor: splenic rupture. Transfus Apher Sci. 2014;50(1):53–55.
98. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604–3611.
99. Hölig K, Blechschmidt M, Kramer M, et al. Peripheral blood stem cell collection in allogeneic donors: impact of venous access. Transfusion. 2012;52(12):2600–2605.
100. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121(1):197–206.
101. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014;123(23):3655–3663.
102. Marmier-Savet C, Larosa F, Legrand F, et al. G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. Blood. 2010;115(4):910–911.
103. Marmier-Savet C, Larosa F, Legrand F, et al. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion. 2010;50(12):2676–2685.
104. Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014; 20(10):1573–1579.
105. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014;14(7):1599–1611.
106. Wikell H, Ponandai-Srinivasan S, Mattsson J, Gertow J, Uhlin M. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation. Transpl Infect Dis. 2014;16(2): 203–212.
107. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2003;44(5):815–820.
108. Wahlin A, Eriksson M, Hultdin M. Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol. 2004;73(4):263–268.
109. Varmavuo V, Mäntymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89(2):128–135.